AU2003268478A1 - Cardiolipin molecules and method of synthesis - Google Patents

Cardiolipin molecules and method of synthesis

Info

Publication number
AU2003268478A1
AU2003268478A1 AU2003268478A AU2003268478A AU2003268478A1 AU 2003268478 A1 AU2003268478 A1 AU 2003268478A1 AU 2003268478 A AU2003268478 A AU 2003268478A AU 2003268478 A AU2003268478 A AU 2003268478A AU 2003268478 A1 AU2003268478 A1 AU 2003268478A1
Authority
AU
Australia
Prior art keywords
synthesis
cardiolipin molecules
cardiolipin
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003268478A
Other languages
English (en)
Inventor
Imran Ahmad
Moghis U. Ahmad
Murali K. Ukkalam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neopharm Inc
Original Assignee
Neopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/013917 external-priority patent/WO2004062569A2/en
Priority claimed from PCT/US2003/016412 external-priority patent/WO2003099830A2/en
Application filed by Neopharm Inc filed Critical Neopharm Inc
Publication of AU2003268478A1 publication Critical patent/AU2003268478A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
AU2003268478A 2002-10-16 2003-09-05 Cardiolipin molecules and method of synthesis Abandoned AU2003268478A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US41927702P 2002-10-16 2002-10-16
US60/419,277 2002-10-16
US42928502P 2002-11-26 2002-11-26
US60/429,285 2002-11-26
US43865903P 2003-01-07 2003-01-07
US60/438,659 2003-01-07
US46733103P 2003-05-02 2003-05-02
US60/467,331 2003-05-02
PCT/US2003/013917 WO2004062569A2 (en) 2003-01-07 2003-05-04 Cardiolipin compositions their methods of preparation and use
AU2003300770 2003-05-04
PCT/US2003/016412 WO2003099830A2 (en) 2002-05-24 2003-05-23 Cardiolipin compositions, methods of preparation and use
AU2003239614 2003-05-23
PCT/US2003/027806 WO2004039817A1 (en) 2002-10-16 2003-09-05 Cardiolipin molecules and method of synthesis

Publications (1)

Publication Number Publication Date
AU2003268478A1 true AU2003268478A1 (en) 2004-05-25

Family

ID=32234368

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003268478A Abandoned AU2003268478A1 (en) 2002-10-16 2003-09-05 Cardiolipin molecules and method of synthesis
AU2003277445A Abandoned AU2003277445A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003277445A Abandoned AU2003277445A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof

Country Status (7)

Country Link
EP (2) EP1556392A1 (de)
JP (2) JP2006510733A (de)
AU (2) AU2003268478A1 (de)
CA (2) CA2502285A1 (de)
EA (2) EA200500659A1 (de)
HK (1) HK1080087A1 (de)
WO (2) WO2004039817A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US20080286351A1 (en) * 2004-06-29 2008-11-20 Ahmad Moghis U Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof
WO2006052906A2 (en) * 2004-11-08 2006-05-18 Neopharm, Inc. Synthesis of cardiolipin analogues and uses thereof
WO2006113679A2 (en) 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions
WO2007014150A2 (en) * 2005-07-22 2007-02-01 Neopharm, Inc. Method of administering liposomes containing oligonucleotides
WO2007065017A2 (en) * 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Oligonucleotide cationic liposomal delivery system
WO2007064857A2 (en) 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Amphoteric liposome formulation
JP2009527576A (ja) * 2006-02-24 2009-07-30 ネオフアーム・インコーポレイテツド カルジオリピン調製の方法および工程
US9750812B2 (en) * 2008-09-27 2017-09-05 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
EP2836229B1 (de) * 2012-04-11 2018-12-05 Lipoxen Technologies Limited Liposome mit oligopeptidfragmenten eines basischen myelinproteins, pharmazeutische zusammensetzung und verfahren zur behandlung von multipler sklerose

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2113606A (en) * 1934-05-24 1938-04-12 Alba Pharmaceutical Company In Quaternary ammonium compounds
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane
NZ512244A (en) * 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
CA2375727C (en) * 1999-05-28 2010-05-25 Vical Incorporated Cytofectin dimers and methods of use thereof

Also Published As

Publication number Publication date
WO2004039817A1 (en) 2004-05-13
EA200500661A1 (ru) 2005-10-27
EP1556392A1 (de) 2005-07-27
EA200500659A1 (ru) 2005-10-27
WO2004035523B1 (en) 2004-08-26
WO2004035523A1 (en) 2004-04-29
JP2006510733A (ja) 2006-03-30
WO2004039817A9 (en) 2004-07-22
AU2003277445A1 (en) 2004-05-04
CA2501990A1 (en) 2004-04-29
EP1558562A1 (de) 2005-08-03
JP2006503112A (ja) 2006-01-26
HK1080087A1 (zh) 2006-04-21
CA2502285A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
AU2003215121A1 (en) Dvd and method of using same
HK1080087A1 (zh) 心磷脂分子和其合成方法
AU2003288999A1 (en) Display unit and method of fabricating display unit
AU2003232408A1 (en) System and method of providing media content
AU2003230957A1 (en) Quantitation of biological molecules
AU2003282558A1 (en) Nanopellets and method of making nanopellets
IL166535A0 (en) Modified adamts4 molecules and method of use thereof
AU2003250956A1 (en) Proteomic screen to identify disease-related biological molecules and inhibitors thereto
AU2002346548A1 (en) Regioisomerically pure oxochlorins and methods of synthesis
AU2003260291A1 (en) Proximity-aided synthesis of templated molecules
AU2003219824A1 (en) Fluorinated molecules and methods of making and using same
AU2002326580A1 (en) Computer-based methods of designing molecules
AU2002255495A1 (en) Methods of identifying regulator molecules
AU2003244120A1 (en) Case for computer and method of producing the case
AU2003280588A1 (en) Label and method of producing the same
AU2003213365A1 (en) Prism and method of producing the same
AU2003260909A1 (en) Method of enhancing multimedia
AU2003216354A1 (en) Modulators of paraptosis and related methods
AUPS187002A0 (en) Condition-specific molecules and uses therefor
AU2003225471A1 (en) System and method of authentifying
AU2003238443A1 (en) Separation of molecules
AU2003255804A1 (en) Comparison of molecules using field points
AU2003261362A1 (en) Lipid binding molecules and methods of use
AU2003284420A1 (en) Method of constructing assigned molecule and library comprising the same and method of using the same
AU2003277950A1 (en) Panel and method of creation

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase